Targeting this pathway with anti-IL-1α antibodies or the IL-1 receptor 1 (IL-1R1) blocker anakinra at the onset of tumor formation not only retards tumor progression but also restores myelopoiesis in older mice. This evidence concerns the gene IL1A and neoplasm.